Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Datopotamab-deruxtecan 联合 durvalumab 治疗早期乳腺癌:序贯多重分配随机 I-SPY2.2 II 期试验
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-03267-1
Shatsky, Rebecca A; Trivedi, Meghna S; Yau, Christina; Nanda, Rita; Rugo, Hope S; Davidian, Marie; Tsiatis, Butch; Wallace, Anne M; Chien, A Jo; Stringer-Reasor, Erica; Boughey, Judy C; Omene, Coral; Rozenblit, Mariya; Kalinsky, Kevin; Elias, Anthony D; Vaklavas, Christos; Beckwith, Heather; Williams, Nicole; Arora, Mili; Nangia, Chaitali; Roussos Torres, Evanthia T; Thomas, Brittani; Albain, Kathy S; Clark, Amy S; Falkson, Carla; Hershman, Dawn L; Isaacs, Claudine; Thomas, Alexandra; Tseng, Jennifer; Sanford, Amy; Yeung, Kay; Boles, Sarah; Chen, Yunni Yi; Huppert, Laura; Jahan, Nusrat; Parker, Catherine; Giridhar, Karthik; Howard, Frederick M; Blackwood, M Michele; Sanft, Tara; Li, Wen; Onishi, Natsuko; Asare, Adam L; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L; Matthews, Jeffrey B; Moore, Brian; Symmans, W Fraser; Price, Elissa; Heditsian, Diane; LeStage, Barbara; Perlmutter, Jane; Pohlmann, Paula; DeMichele, Angela; Yee, Douglas; van 't Veer, Laura J; Hylton, Nola M; Esserman, Laura J